The predictive value of contrast-enhanced ultrasound parameters combined with serum CXCL9 and IGFBP-3 for recurrence of hepatocellular carcinoma after interventional therapy
MO Min
LIN Jingjing
LU Xin
LU Jin
Abstract：Objective To evaluate the predictive significance of contrast-enhanced ultrasound parameters in combination with serum levels of chemokine ligand 9(CXCL9)and insulin-like growth factor-binding protein 3(IGFBP-3)for the recurrence of hepatocellular carcinoma following interventional therapy.Methods A total of 212 patients with liver cancer who received interventional therapy at the hospital between June 2022 and Novem-ber 2023 were selected and categorized into Group A(61 cases)and Group B(151 cases)based on whether tumor recurrence occurred within one year following the intervention.Multivariate logistic regression analysis was con-ducted to identify potential influencing factors associated with post-treatment recurrence.The predictive perfor-mance of contrast-enhanced ultrasound parameters combined with serum biomarkers was evaluated using receiver operating characteristic(ROC)curve analysis.Results The levels of several factors including a tumor with a maximum diameter exceeding 3 cm,presence of microvascular invasion,high peak intensity(PI),short time to peak(TTP),short arrival time(AT),elevated serum CXCL9,and decreased serum IGFBP-3 were identified as indepen-dent risk factors for recurrence in patients with hepatocellular carcinoma following interventional therapy(P<0.05).The area under the curve(AUC)for the combination of PI,TTP,AT,along with serum levels of CXCL9 and IGFBP-3,in predicting recurrence after interventional therapy was significantly higher than that of individual fac-tors alone(P<0.05).Conclusions The risk of recurrence in patients undergoing interventional therapy for liver cancer is substantial,and it is influenced by a range of independent risk factors.Combining contrast-enhanced ul-trasound parameters with serum levels of CXCL9 and IGFBP-3 may enhance the predictive accuracy for tumor re-currence in these patients.
Keywords：hepatocellular carcinomaintervention therapycontrast-enhanced ultrasound param-eterschemokine ligand 9insulin-like growth factor binding protein 3
Publication Date：2025-08-25
Online Publishing Date：2025-09-04(First online date of this platform, not the publication date of the document)
Pages：7( 2568-2574 )